🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07211269
Recruiting Not applicable

Individual Differences in Cognitive Control Predict Real-time fMRI Neurofeedback Performance

NCT07211269 · tracked via the Priya Life Science China tracker
Sponsor
University of Electronic Science and Technology of China
Phase
Not applicable
Started
2025-09-03
Last updated
2025-10-07

Condition(s) studied

Healthy

Investigational drug(s) / intervention(s)

Real-time fMRI neurofeedback training

Real-time fMRI neurofeedback training: Real-time neurofeedback information is computed using the Turbo Brain voyager (TBV) 4.0 software (Brain Innovation, Maastricht, The Netherlands). Functional images are collected and processed in real time based on contrasts of regulation vs. rest conditions. The BOLD signal of the target region is then transformed into visual bars and displayed to participants via the projector screen while participants keep using regulation strategy (heartbeat interoception in our study) to upregulate the target region.

Study summary

The goal of this study is to investgate whether individual differences of cognitive control capacity could predict neurofeedback performance and the behavioral effects resulting from successful anterior insula regulation via interoceptive strategy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Healthy subjects without any past or present psychiatric or neurological disorders Exclusion Criteria: * History of brain injury Medical or mental illness and color blindness or weakness. * The presence of metal in the body or claustrophobia.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Electronic Science and Technology of China Chengdu Chengdu Recruiting

More University of Electronic Science and Technology of China trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07211269 on ClinicalTrials.gov ↗ ← All trials in China